Pharma China (www.pharmachinaonline.com) is the most influential English media and source of business intelligence covering the Chinese pharmaceutical sector. Pharma China caters for the growing needs of the international pharmaceutical industry for up-to-date and insightful information and intelligence on China’s burgeoning but increasingly complex healthcare marketplace, and is subscribed by most MNC pharma companies, leading CROs, investment banks, consulting firms active in China as well as relevant industry associations and government agencies.

Note: To view full text of free articles, you need to register as a basic member first and then log in. To view premium articles, you need to subscribe to Pharma China as a premium member. For more information or subscription, please contact info@pharmachinaonline.com. If you wish to unsubscribe from this e-Alert, please reply this e-mail with "Remove" in the subject line.
Is Renewed MNC Optimism in China Sustainable amid Intensified Cost Containment and Slowing Economy?(12/3/2018 )  (Premium)
Editor´s Picks
Wuxi AppTec Says US Hurdles Will Not Dim Acquisition Appetite(12/5/2018 )  (Premium)
BeiGene Mounts Its Assault On The Ibrutinib Hegemony(12/5/2018 )  (Premium)
US Biotech Firms Made China's Gene-Edited Babies Possible(12/4/2018 )  (Premium)
U.S.-China Trade Tensions Threaten Biotech Cash Surge(12/4/2018 )  (Premium)
J&J to Build Blood-Cancer Push With Controversial China Biotech(12/4/2018 )  (Premium)
The Market
SMEI President Predicts Continued Chinese Pharma Growth in 2019(12/4/2018 )  (Premium)
Industry News
Gilead Launches HBV Drug Vemlidy in China(12/9/2018 )  (Premium)
Brii Bio Announced Partnerships to Jump-start Pipeline with Focus on Hepatitis(12/7/2018 )  (Premium)
Oral Insulin Moves Towards Becoming Reality in U.S., China(12/7/2018 )  (Premium)
IFPMA and RDPAC Introduce New Code for Pharmaceutical Marketing Practices(12/7/2018 )  (Premium)
Changzhou Qianhong Biopharma Expands Facility for Polysaccharides and Enzyme Drugs(12/5/2018 )  (free)
PAREXEL and Eli Lilly to Develop Chinese Clinical Research Workforce(12/5/2018 )  (Premium)
NMPA Approves Gilead's HIV Combo Drug Descovy(12/5/2018 )  (Premium)
Insurer Manulife-Sinochem Inks Deal with Healthcare Platform 111 Inc.(12/5/2018 )  (Premium)
China Approves New Indication of J&J's Prostate Cancer Drug ZYTIGA(12/5/2018 )  (Premium)
Revance Licenses China Rights of Neuromodulator RT002 to Fosun Pharma(12/4/2018 )  (Premium)
Roche¡¯s Hemlibra (emicizumab) Approved for Import and Marketing in China(12/4/2018 )  (Premium)
Elpiscience Raises $35 Mln in A+ Round Led by Hillhouse Capital(12/4/2018 )  (Premium)
Sartorius and Immunochina Partner to Advance Immunotherapy Development(12/4/2018 )  (free)
AstraZeneca to Promote R&D of Seven New Drugs in China(12/3/2018 )  (Premium)
CASI Pharma Announces Chinese Approval of EVOMELA(12/3/2018 )  (Premium)
Helsinn and Mundipharma China Announce Approval of ALOXI IV by the NMPA(12/3/2018 )  (Premium)
Regulatory News
SAMR Fines Three Violators as It Steps Up Anti-monopoly Crackdown on API Price Hikes(12/7/2018 )  (Premium)
General Health
National Centralized Drug Purchase Trial Upsets Pharma Industry with Cut-throat Price Cuts(12/7/2018 )  (Premium)
NHC and SMIA Reach Consensus about Use of HTA for BMI Reimbursement Listing(12/3/2018 )  (Premium)
Legal/IPR News
State Council Approves Patent Amendment Draft and Policies to Boost Innovation(12/7/2018 )  (Premium)
China Introduces A Range of New Punishments for IP Violations(12/5/2018 )  (Premium)
Product/R&D News
Innovent Gains US FDA Approval to Initiate Clinical Trials for its Anti-OX40 mAb IBI101(12/5/2018 )  (Premium)
Shionogi/Roche's Flu New Drug Xofluza Submits IND in China(12/3/2018 )  (Premium)
People in the News
Recent Executive Moves(12/7/2018 )  (Premium)
© Wicon International Group¡¡Support by: www.heightow.com Home | Site map | Contact Us | Links